Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Forst

Showing results (11-20 of 148) with videos related to

Pageof 15
Sort By:
Expert Opinion on Pharmacotherapy|May 20, 2014
Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metforminThomas Forst, Peter Bramlage
Diabetes Care|March 5, 2002
Response to Jungheim and KoschinskyAndreas Pfützner, Thomas Forst
Diabetes Technology & Therapeutics|February 14, 2006
High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitusAndreas Pfützner, Thomas Forst
Expert Review of Endocrinology & Metabolism|February 9, 2019
Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitusThomas Forst, Andreas Pfützner
Expert Opinion on Pharmacotherapy|June 7, 2011
Review of approved pioglitazone combinations for type 2 diabetesThomas Forst, Markolf Hanefeld, Andreas Pfützner
Current Medical Research and Opinion|April 14, 2015
Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week studyThomas Forst, Cornelia Koch, Markus Dworak
Vascular Health and Risk Management|June 22, 2007
Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combinationAndreas Pfützner, Birgit Wilhelm, Thomas Forst
Clinical Laboratory|February 17, 2009
A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitusAndreas Pfützner, Matthias M Weber, Thomas Forst
Expert Opinion on Pharmacotherapy|August 19, 2007
Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effectsAndreas Pfützner, Matthias M Weber, Thomas Forst
Experimental Diabetes Research|May 12, 2012
Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic controlThomas Forst, Matthias M Weber, Andreas Pfützner
Pageof 15

Showing results (11-20 of 148) with videos related to

Sort By:
Pageof 15
Expert Opinion on Pharmacotherapy|May 20, 2014
Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metforminThomas Forst, Peter Bramlage
Diabetes Care|March 5, 2002
Response to Jungheim and KoschinskyAndreas Pfützner, Thomas Forst
Diabetes Technology & Therapeutics|February 14, 2006
High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitusAndreas Pfützner, Thomas Forst
Expert Review of Endocrinology & Metabolism|February 9, 2019
Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitusThomas Forst, Andreas Pfützner
Expert Opinion on Pharmacotherapy|June 7, 2011
Review of approved pioglitazone combinations for type 2 diabetesThomas Forst, Markolf Hanefeld, Andreas Pfützner
Current Medical Research and Opinion|April 14, 2015
Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week studyThomas Forst, Cornelia Koch, Markus Dworak
Vascular Health and Risk Management|June 22, 2007
Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combinationAndreas Pfützner, Birgit Wilhelm, Thomas Forst
Clinical Laboratory|February 17, 2009
A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitusAndreas Pfützner, Matthias M Weber, Thomas Forst
Expert Opinion on Pharmacotherapy|August 19, 2007
Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effectsAndreas Pfützner, Matthias M Weber, Thomas Forst
Experimental Diabetes Research|May 12, 2012
Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic controlThomas Forst, Matthias M Weber, Andreas Pfützner
Pageof 15